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Synthesis of the cyclic N-Methylated compounds 
 
All peptides were manually assembled on a 2-chlorotritylchloride resin applying Fmoc-
based SPPS. Loading of the resin with 1 mmol amino acid: resin was achieved using 1.1 
mmol of Fmoc-Xaa-OH according to the published procedure.[1] Synthesis was carried 
out using 2.5 equivalents of Fmoc-Xaa-OH: TBTU/HOBt and DIPEA in N-methyl-2-
pyrrolidon (NMP) for coupling of normal amino acids, HATU/HOAt and DIPEA in 
NMP for N-alkylated amino acids and 20% piperidine in DMF for cleavage of the Fmoc 
moiety. Treatment of the resin with acetic acid (HOAc)/TFE/DCM (1/1/3) for 1 h and 
removal of the solvent yielded the linear peptides.[2] Addition of 3 equivalents of DPPA 
and 5 equivalents of solid NaHCO3 and subsequent stirring for 24 h gave the crude cyclic 
peptides after evaporation of the solvent. Purification of the cyclopeptides was achieved 
by RP-HPLC on C18 columns. N-methylated alanine was synthesized according to the 
procedure of Freidinger et al. [3] and N-methylated lysine according to Biron et al.[4] 
 
NMR Spectroscopy 
All spectra were recorded at 300 K on a 500 MHz Bruker DMX spectrometer (Bruker, 
Karlsruhe, Germany) in d6-DMSO and were processed using XWINNMR or TOPSPIN 
(Bruker) and analyzed with either XWINNMR, TOPSPIN, or SPARKY.[5] The 
assignment of proton and carbon resonances followed a strategy described in literature.[6] 
Sequential assignment was accomplished by through-bond connectivities from 
heteronuclear multiple bond correlation (HMBC)[7] spectra whereas N-methyl groups 
served as starting point. Connectivities were proved by interresidual scalar couplings, e.g 
between carbonyl carbons and adjacent amide protons. TOCSY spectra[8] were recorded 
with a mixing time of 60 ms, ROESY spectra[9] with a mixing time of 150 ms, thus 
avoiding unwanted effects caused by spin diffusion. Several compounds show more than 
one conformation that are in slow exchange at the NMR time scale. Conformational 
exchange was proven by detection of inverted signal signs in ROESY spectra.[10] 
Evidence of cis peptide bonds in proline containing peptides was achieved using carbon 
shifts in DEPT45 spectra.[11] The ratio of different conformational populations was 
determined via the integrals of amide and Ha-signals in 1H-1D spectra. 
 
In Vitro Inhibition of Protein-Protein Binding. avb3 Binding 
Assay.  
The inhibiting activity of the integrin inhibitors was determined in a solid-phase binding 
assay using coated avb3 integrin and soluble biotinylated extracellular matrix protein 
vitronectin. The assay was based on a previously reported method with some 
modifications.[12] BRAND flat-bottom 96-well ELISA plates were coated overnight at 
room temperature with 100 µL/well of 0.4 µg/mL human avb3 (Chemicon) in TS-buffer 
(20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, pH 7.5). 
Plates were subsequently washed three times with PBST buffer (137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 2 mM  KH2PO4, 0.01% Tween 20, pH 7.4) and blocked for 2 h at 
30 °C with 150 µL/well of TSB-buffer (TS-buffer containing 1% BSA). After being 
washed three times with PBST, controls or test compounds (0.0003 to 10 µM) were 
mixed with 1 µg/mL human vitronectin (Chemicon), which was biotinylated in-house 
with sulfo-NHS-LC-LC-Biotin (Pierce, 20:1 molar ratio), and 100 µL of these solutions 
were incubated for 2 h at 30 °C. The plate was then washed five times with PBST buffer 
and 100 µL/well of 0.25 µg/mL NeutrAvidin-horseradish peroxidase conjugate (Pierce) 
were added to the plate and incubated for 1 h at 30 °C. After washing 5 times with PBST, 
the plate was developed by adding 100 µL/well of OPD buffer (1 mg/2.5 mL o-
phenylenediamine dihydrochloride, 50 mM Na2HPO4, 24 mM sodium citrate, 0.04 % 
H2O2 (30%), pH 5.0) at room temperature. The reaction was stopped with 50 µL/well of 
2 M H2SO4, and the absorbance was measured at 492 nm with a POLARstar Galaxy plate 
reader (BMG Labtechnologies). Every concentration was analyzed by duplicate and the 
resulting inhibition curves were analyzed using OriginPro 7.5G software, the turning 
point describes the IC50 value. 
 
Computational methods  
Proton distances were calculated according to the isolated two-spin approximation from 
volume integrals of ROESY spectra [13]. No ROE offset correction was performed since 
biasing offset effects at the field strength used in this study are rather small. The 
integrated volumes of ROE cross peaks were converted to proton–proton distances by the 
help of calibration to an averaged alanine Ha–Hb* distance as reference (2.45 Å; 
including pseudo-atom correction). Upper and lower distance restraints were obtained by 
adding and subtracting 10% to the calculated experimental values, thus accounting for 
experimental errors and simulation uncertainties. Metric matrix DG calculations were 
carried out with a (slightly modified version) distance geometry program utilizing 
random metrization.[14] Experimental distance restraints which are more restrictive than 
the geometric distance bounds (holonomic restraints) were used to create the final 
distance matrix. All structure templates were first embedded in four dimensions and then 
partially minimized using conjugate gradient minimization followed by distance-driven 
dynamics (DDD)[15] wherein only distance constraints were used. The DDD simulation 
was carried out at 1000 K for 50 ps with a gradual reduction in temperature over the next 
30 ps. The DDD procedure utilized holonomic and experimental distance constraints plus 
a chiral penalty function for the generation of violation energies and forces. A distance 
matrix was calculated from each structure, and the EMBED algorithm was used to 
compute Cartesian coordinates in three dimensions. 100 structures were calculated for 
each peptide, and > 90% of the structure bundle of each peptide did not show any 
significant violations (> 0.2 Å). Molecular Dynamics calculations were carried out with 
the program DISCOVER using the CVFF force field.[16] Structures resulting from DG 
calculations were placed in a cubic box with a vector length of 3.0 nm and soaked with 
DMSO. Intramolecular distances of the peptides were kept constant according to the 
experimental values. After energy minimization using steepest descent and conjugate 
gradient algorithms, the system was gradually heated in 50 K steps (equilibration time at 
each temperature was 2 ps) starting from 10 K, each by direct scaling of velocities. The 
system was equilibrated for 50 ps with temperature bath coupling (300 K). 
Configurations in the subsequent production runs (150 ps) were saved every 100 fs. 
Finally, 150 ps free MD simulations at 300 K were carried out in order to prove that no 
significant structural changes occur when no distance restraints are present during the 
simulation. 
Analytical Data 
 
Compound 
No 
Sequence Mass(ESI), 
(M+H+)+ 
HPLC (10-90%) 
30 min 
1H-NMR 
1 cyclo(-a-A-A-MeA-A-) 370.2 7.79 
 
 
               1H,1H-TOCSY: Assignment of trans conformation                               1H,1H-TOCSY: Assignment of cis conformation 
 
 
 
 
 
 
 
1H,1H-ROESY: black: diagonal and conformational exchange peaks; blue: ROE cross peaks 
 
 
1H,13C-HMBC: left: section of C-H and C-H3 proton-carbon peaks; right: section of carbonyl carbons (weaks peaks belong to not-fully filtered 
1J-CH couplings; peaks between 140-155 ppm in the indirect dimension are artefacts arising from aliphatic CH coupled peaks) 
 
2 cyclo(-t-A-A-MeA-A-) 400.3 6.95 
 
3 cyclo(-a-T-A-MeA-A-) 400.2 7.38 
 
4 cyclo(-a-A-T-MeA-A-) 400.1 7.56 
 
5 cyclo(-a-A-A-MeT-A-) 400.2 7.03 
 
6 cyclo(-a-A-A-MeA-T-) 400.1 6.97 
 
7 cyclo(-v-A-A-MeA-A-) 398.5 10.17 
 
8 cyclo(-a-V-A-MeA-A-) 398.3 10.37 
 
9 cyclo(-a-A-V-MeA-A-) 398.5 10.76 
 
10 cyclo(-a-A-A-MeV-A-) 398.4 11.66 
 
11 cyclo(-a-A-A-MeA-V-) 398.2 11.15 
 
12 cyclo(-i-A-A-MeA-A-) 412.5 13.11 
 
13 cyclo(-a-I-A-MeA-A-) 412.5 12.07 
 
14 cyclo(-a-A-I-MeA-A-) 412.5 12.48 
 
15 cyclo(-a-A-A-MeI-A-) 412.6 14.03 
 
16 cyclo(-a-A-A-MeA-I-) 412.3 13.00 
 
17 cyclo(-l-A-A-MeA-A-) 412.4 12.52 
 
18 cyclo(-a-L-A-MeA-A-) 412.6 12.51 
 
19 cyclo(-a-A-L-MeA-A-) 412.5 13.12 
 
20 cyclo(-a-A-A-MeL-A-) 412.6 13.65 
 
21 cyclo(-a-A-A-MeA-L-) 412.6 13.44 
 
22 cyclo(-s-A-A-MeA-A-) 386.2 6.62 
 
23 cyclo(-a-S-A-MeA-A-) 386.4 7.01 
 
24 cyclo(-a-A-S-MeA-A-) 386.1 7.31 
 
25 cyclo(-a-A-A-MeS-A-) 386.4 6.37 
 
26 cyclo(-a-A-A-MeA-S-) 386.3 7.32 
 
27 cyclo(-n-A-A-MeA-A-) 413.1 5.89 
 
28 cyclo(-a-N-A-MeA-A-) 413.2 6.31 
 
29 cyclo(-a-A-N-MeA-A-) 413.0 6.15 
 
30 cyclo(-a-A-A-MeN-A-) 413.2 6.11 
 
31 cyclo(-a-A-A-MeA-N-) 413.2 5.88 
 
32 cyclo(-k-A-A-MeA-A-) 427.5 6.78 
 
33 cyclo(-a-K-A-MeA-A-) 427.5 6.95 
 
34 cyclo(-a-A-K-MeA-A-) 427.3 6.78 
 
35 cyclo(-a-A-A-MeK-A-) 427.5 6.39 
 
36 cyclo(-a-A-A-MeA-K-) 427.3 6.35 
 
37 cyclo(-d-A-A-MeA-A-) 414.1 7.04 
 
38 cyclo(-a-D-A-MeA-A-) 414.2 7.30 
 
39 cyclo(-a-A-D-MeA-A-) 414.4 6.98 
 
40 cyclo(-a-A-A-MeD-A-) 414.1 6.94 
 
41 cyclo(-a-A-A-MeA-D-) 414.5 7.05 
 
42 cyclo(-f-A-A-MeA-A-) 446.4 17.11 
 
43 cyclo(-a-F-A-MeA-A-) 446.5 17.26 
 
44 cyclo(-a-A-F-MeA-A-) 446.5 13.68 
 
45 cyclo(-a-A-A-MeF-A-) 446.5 14.46 
 
46 cyclo(-a-A-A-MeA-F-) 446.4 14.27 
 
47 cyclo(-w-A-A-MeA-A-) 485.2 13.90 
 
48 cyclo(-a-W-A-MeA-A-) 485.1 14.82 
 
49 cyclo(-a-A-W-MeA-A-) 485.1 14.73 
 
50 cyclo(-a-A-A-MeW-A-) 485.0 15.04 
 
51 cyclo(-a-A-A-MeA-W-) 485.1 14.62 
 
52 cyclo(-f-MeK-R-G-D-) 618.7 10.84 (10-50% 
ACN) 
 
 
 
Structure Calculation Data 
 
Peptide cyclo (-a-A-A-MeA-A-)   -   trans 
No Res-No Res Atom Res-No Res Atom Up (Å) Low (Å) Dist (Å) Viol (Å) 
01 1 DLA HA 1 DLA HN 3.05 2.49 2.80  
02 1 DLA HA 2 ALA HN 2.32 1.90 2.18  
03 5 ALA HB* 5 ALA HN 3.88 2.36 2.87  
04 1 DLA HB* 1 DLA HA 3.38 1.94 2.40  
05 1 DLA HB* 1 DLA HN 3.83 2.31 2.83  
06 1 DLA HN 5 ALA HA 2.40 1.96 2.22  
07 2 ALA HA 3 ALA HN 3.35 2.75 3.45 + 0.10 
08 2 ALA HB* 2 ALA HA 3.39 1.95 2.41  
09 2 ALA HB* 2 ALA HN 3.80 2.30 2.80  
10 2 ALA HB* 3 ALA HN 4.60 2.94 3.17  
11 2 ALA HN 3 ALA HN 2.75 2.25 2.48  
12 3 ALA HA 3 ALA HN 3.07 2.51 2.83  
13 3 ALA HB* 3 ALA HA 3.41 1.97 2.39  
 
Peptide cyclo (-a-A-A-MeA-A-)   -   cis 
No Res-No Res Atom Res-No Res Atom Up (Å) Low (Å) Dist (Å) Viol (Å) 
01 5 ALA HA 5 ALA HN 2.91 2.39 2.63  
02 5 ALA HB* 5 ALA HN 4.06 2.50 2.73  
03 5 ALA HB* 1 DLA HN 4.11 2.55 3.92  
04 5 ALA HN 4 NLA HA 3.14 2.56 3.28 + 0.14 
05 1 DLA HB* 1 DLA HN 4.00 2.46 2.85  
06 2 ALA HA 3 ALA HN 3.74 3.06 2.87 - 0.19 
07 2 ALA HN 1 DLA HA 2.68 2.20 2.25  
08 2 ALA HB* 2 ALA HN 4.02 2.48 2.92  
09 3 ALA HB* 3 ALA HN 3.88 2.36 3.14  
10 3 ALA HN 3 ALA HA 3.04 2.48 2.57  
11 3 ALA HN 4 NLA HA 3.55 2.90 3.55  
12 4 NLA HB* 5 ALA HN 4.30 2.70 3.12  
13 4 NLA HB* 4 NLA HA 3.29 1.87 2.39  
 
 
 
 
 
 
 
Energetic Differences between the Conformations 
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